4-[(9Z,28Z)-heptatriaconta-9,28-dien-19-yl]-1-methylpyridin-1-ium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-[(9Z,28Z)-heptatriaconta-9,28-dien-19-yl]-1-methylpyridin-1-ium
• 化学式: C43H78N+
• 分子量: 609.1
• InChiKey: UJCKLFHNYNJNPS-AUYXYSRISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  18.7
• 重原子数：
  44
• 可旋转键数：
  33
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  3.9
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] BRANCHED PEG MOLECULES AND RELATED COMPOSITIONS AND METHODS<br/>[FR] MOLÉCULES DE PEG RAMIFIÉ, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS
  申请人：PHASERX INC

  公开号：WO2018126084A1

  公开（公告）日：2018-07-05

  Disclosed are branched PEG molecules, including branched PEG-lipids and branched-PEG proteins, as well as related compositions and methods for making branched PEG molecules. Also disclosed are related compositions, systems, and methods for in vivo delivery of therapeutic and diagnostic agents.

  揭示了分支聚乙二醇（PEG）分子，包括分支PEG-脂质和分支PEG-蛋白质，以及制备分支PEG分子的相关组合物和方法。还公开了相关的组合物、系统和方法，用于体内传递治疗和诊断试剂。
• Micrornas in neurodegenerative disorders
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US10184151B2

  公开（公告）日：2019-01-22

  Provided herein are methods of treating a neurodegenerative disorder such as Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) that include administering to a subject at least one inhibitory nucleic acid that decreases the level or activity of microRNA hsa-miR-155.

  本文提供了治疗神经退行性疾病（如肌萎缩侧索硬化症（ALS）或多发性硬化症（MS））的方法，包括向受试者施用至少一种可降低 microRNA hsa-miR-155 水平或活性的抑制性核酸。
• Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
  申请人：GENEVANT SCIENCES GMBH

  公开号：US11219634B2

  公开（公告）日：2022-01-11

  Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.

  所公开的是将治疗剂或诊断剂输送到受试者细胞的细胞质中的方法。所公开的方法一般包括向受试者施用有效量的脂质纳米粒子，该纳米粒子包含治疗剂或诊断剂以及有效量的膜失稳聚合物。还公开了相关的组合物和给药系统。
• Lipid nanoparticle composition
  申请人：Suzhou Abogen Biosciences Co., Ltd.

  公开号：US11472766B2

  公开（公告）日：2022-10-18

  Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination.

  本文提供的脂质可与其他脂质成分（如中性脂质、胆固醇和聚合物共轭脂质）结合使用，形成脂质纳米粒子，用于递送治疗剂（如核酸分子），以达到治疗或预防目的，包括接种疫苗。
• NOUVELLE CLASSE DE LIPIDES CATIONIQUES POUR LE TRANSPORT D'AGENTS ACTIFS DANS LES CELLULES
  申请人：Oz Biosciences Sas

  公开号：EP2285772A2

  公开（公告）日：2011-02-23